Citations

Showing 10 of 108119 citations.

Diet- and Lifestyle‐Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance)
Cheng, En , Ou, Fang‐Shu , Ma, Chao , Spiegelman, Donna , Zhang, Sui , Zhou, Xin , Bainter, Tiffany M., Niedzwiecki, Donna , Whittom, Renaud , Hantel, Alexander, Benson, Al B. , Atienza, Daniel, Messino, Michael J., Kindler, Hedy L. , Giovannucci, Edward L. , Blarigan, Erin L. Van , Ng, Kimmie , Gross, Cary P. , Meyerhardt, Jeffrey A. , Fuchs, Charles S. , Saltz, Leonard , Niedzwiecki, Donna , Benson, Al , Kindler, Hedy , Giovannucci, Edward L , Van Blarigan, Erin L , Brown, Justin C , Ng, Kimmie , Fuchs, Charles S , Meyerhardt, Jeffrey A , Ou, Fang-Shu , Saltz, Leonard B. , Mayer, Robert J. , Brown, Justin C. , Cheng, En

Mayo Clinic

Journal of Clinical Oncology | January 7, 2022 | Volume: 40 | Issue: 7 | Pages: 740-751

10.1200/jco.21.01784 | PMID 34995084 Get It

PURPOSECurrent tools in predicting survival outcomes for patients with colon cancer predominantly rely on clinical and pathologic characteristics, but increasing evidence suggests that diet and lifestyle habits are associated with patient outcomes and should be considered to enhance model accuracy.METHODSUsing an adjuvant chemotherapy trial for stage III colon cancer (CALGB 89803), we developed prediction models of disease-free survival (DFS) and overall survival by additionally incorporating self-reported nine diet and lifestyle factors. Both models were assessed by multivariable Cox proportional hazards regression and externally validated using another trial for stage III colon cancer (CALGB/SWOG 80702), and visual nomograms of prediction models were constructed accordingly. We also proposed three hypothetical scenarios for patients with (1) good-risk, (2) average-risk, and (3) poor-risk clinical and pathologic features, and estimated their predictive survival by considering clinical and pathologic features with or without adding self-reported diet and lifestyle factors.RESULTSAmong 1,024 patients (median age 60.0 years, 43.8% female), we observed 394 DFS events and 311 deaths after median follow-up of 7.3 years. Adding self-reported diet and lifestyle factors to clinical and pathologic characteristics meaningfully improved performance of prediction models (c-index from 0.64 [95% CI, 0.62 to 0.67] to 0.69 [95% CI, 0.67 to 0.72] for DFS, and from 0.67 [95% CI, 0.64 to 0.70] to 0.71 [95% CI, 0.69 to 0.75] for overall survival). External validation also indicated good performance of discrimination and calibration. Adding most self-reported favorable diet and lifestyle exposures to multivariate modeling improved 5-year DFS of all patients and by 6.3% for good-risk, 21.4% for average-risk, and 42.6% for poor-risk clinical and pathologic features.CONCLUSIONDiet and lifestyle factors further inform current recurrence and survival prediction models for patients with stage III colon cancer.
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-4
Mayer, Erica L. , Fesl, Christian , Hlauschek, Dominik, Garcia-Estevez, Laura, Burstein, Harold J., Wette, Viktor, Miller, Kathy D., Balic, Marija, Mayer, Ingrid A. , Cameron, David , Winer, Eric P., Lorenzo, José Juan Ponce , Lake, Diana, Pristauz-Telsnigg, Gunda, Haddad, Tufia C. , Shepherd, Lois, Cardoso, Fátima , Sabanathan, Dhanusha, Breitenstein, Urs, Ackerl, Kerstin, Zehetner, Karin, Solomon, Kadine, El-Abed, Sarra , Theall, Kathy Puyana, Lu, Dongrui R. , Dueck, Amylou C. , Miller, Kathy D. , Hlauschek, Dominik , Zdenkowski, Nicholas , Mayer, IA , Cameron, David , Ponce Lorenzo, José Juan , Haddad, Tufia C , Iwata, Hiroji , Goetz, Matthew P , Cardoso, Fatima , Traina, Tiffany A , Metzger Filho, Otto , El-Abed, Sarra , Lu, Dongrui R , Dueck, A. C. , Gnant, Michael , DeMichele, Angela , Mayer, Erica L , Miller, Kathy D , Fesl, Christian , Garcia-Estevez, Laura, Burstein, Harold J., Wette, Viktor, Miller, Kathy D., Balic, Marija, Winer, Eric P., Lake, Diana, Pristauz-Telsnigg, Gunda, Shepherd, Lois, Sabanathan, Dhanusha, Breitenstein, Urs, Ackerl, Kerstin, Zehetner, Karin, Solomon, Kadine, Theall, Kathy Puyana

Mayo Clinic

Journal of Clinical Oncology | January 7, 2022 | Volume: 40 | Issue: 5 | Pages: 449-458

10.1200/jco.21.01918 | PMID 34995105 Get It

PURPOSE The PALLAS study investigated whether the addition of palbociclib, an oral CDK4/6 inhibitor, to adjuvant endocrine therapy (ET) improves invasive disease-free survival (iDFS) in early hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer. In this analysis, we evaluated palbociclib exposure and discontinuation in PALLAS. METHODS Patients with stage II-III HR+, HER2– disease were randomly assigned to 2 years of palbociclib with adjuvant ET versus ET alone. The primary objective was to compare iDFS between arms. Continuous monitoring of toxicity, dose modifications, and early discontinuation was performed. Association of baseline covariates with time to palbociclib reduction and discontinuation was analyzed with multivariable competing risk models. Landmark and inverse probability weighted per-protocol analyses were performed to assess the impact of drug persistence and exposure on iDFS. RESULTS Of the 5,743 patient analysis population (2,840 initiating palbociclib), 1,199 (42.2%) stopped palbociclib before 2 years, the majority (772, 27.2%) for adverse effects, most commonly neutropenia and fatigue. Discontinuation of ET did not differ between arms. Discontinuations for non–protocol-defined reasons were greater in the first 3 months of palbociclib, and in the first calendar year of accrual, and declined over time. No significant relationship was seen between longer palbociclib duration or ≥ 70% exposure intensity and improved iDFS. In the weighted per-protocol analysis, no improvement in iDFS was observed in patients receiving palbociclib versus not (hazard ratio 0.89; 95% CI, 0.72 to 1.11). CONCLUSION Despite observed rates of discontinuation in PALLAS, analyses suggest that the lack of significant iDFS difference between arms was not directly related to inadequate palbociclib exposure. However, the discontinuation rate illustrates the challenge of introducing novel adjuvant treatments, and the need for interventions to improve persistence with oral cancer therapies.
Injection into the Space of Okada During Transforaminal Epidural Steroid Injections
Tiegs‐Heiden, Christin A. , Madhavan, Ajay A. , Diehn, Felix E. , Lehman, Vance T. , Murthy, Naveen S. , Murthy, Naveen S , Madhavan, Ajay A , Tiegs-Heiden, Christin A , Diehn, Felix E

Mayo Clinic

Pain Medicine | January 7, 2022 | Volume: 23 | Issue: 6 | Pages: 1066-1074

10.1093/pm/pnac008 | PMID 35021225 Get It

Abstract Objective Ensuring medication delivery to the epidural space is crucial for effective transforaminal epidural steroid injections. Epidural needle placement is determined by injecting a small amount of contrast at the final needle position. The purpose of this study is to illustrate the appearance of contrast flow in the retrodural retroligamentous space of Okada during computed tomography– and fluoroscopy-guided cervical and lumbar transforaminal epidural steroid injections. Design This retrospective study will use a series of cases to demonstrate contrast within the space of Okada during epidural transforaminal steroid injections. Setting Tertiary medical center. Subjects Study subjects are adult patients who underwent transforaminal epidural steroid injection at our institution. Methods Cases were identified through the use of a search engine of existing radiology reports at our institution. Epidural steroid injection procedural reports were searched for the terms “Okada” and “retrodural space.” Images from the procedure were reviewed by the authors (all proceduralists with dedicated training in spinal injections) to confirm the presence of contrast within the space of Okada. Results This case series illustrates six examples of contrast injection into the retrodural space of Okada during cervical and lumbar transforaminal epidural steroid injections. Conclusions Contrast uptake in the retrodural space of Okada may be seen during transforaminal epidural injections. Although relatively uncommon, it is likely underrecognized. It is extremely important that providers who perform transforaminal epidural steroid injections be familiar with this non-epidural contrast flow pattern so they can adjust needle positioning to deliver steroid to the epidural space.
Comparison of Oncologic Outcomes and Treatment-Related Toxicity of Carbon Ion Radiotherapy and En Bloc Resection for Sacral Chordoma
Yolcu, Yagiz U. , Zreik, Jad, Wahood, Waseem , Bhatti, Atiq ur Rehman , Bydon, Mohamad , Rose, Peter S. , Mahajan, Anita , Petersen, Ivy A. , Haddock, Michael G. , Laack, Nadia N., Jeans, Elizabeth B. , Imai, Reiko , Yamada, Shigeru , Foote, Robert L. , Ahmed, Safia K. , Jethwa, Krishan, Houdek, Matthew T. , Jethwa, Krishan R.

Mayo Clinic

JAMA Network Open | January 7, 2022 | Volume: 5 | Issue: 1 | Pages: e2141927

10.1001/jamanetworkopen.2021.41927 | PMID 34994795 Get It

Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (E2108)
Khan, Seema A. , Zhao, Fengmin, Goldstein, Lori J. , Cella, David , Basik, Mark , Golshan, Mehra, Julian, Thomas B., Pockaj, Barbara A., Lee, Christine A. , Razaq, Wajeeha, Babiera, Gildy V., Dy, Irene A., Jain, Sarika, Silverman, Paula , Fisher, Carla S., Sparano, Joseph A , Silverman, Paula , Tevaarwerk, Amye J , Wagner, Lynne , Sledge, George W , Khan, Seema A. , Zhao, Fengmin, Goldstein, Lori J. , Cella, David , Basik, Mark , Golshan, Mehra, Julian, Thomas B., Pockaj, Barbara A., Lee, Christine A. , Razaq, Wajeeha, Babiera, Gildy V., Dy, Irene A., Jain, Sarika, Fisher, Carla S.

Mayo Clinic

Journal of Clinical Oncology | January 7, 2022 | Volume: 40 | Issue: 9 | Pages: 978-987

10.1200/jco.21.02006 | PMID 34995128 Get It

PURPOSE Distant metastases are present in 6% or more of patients with newly diagnosed breast cancer. In this context, locoregional therapy for the intact primary tumor has been hypothesized to improve overall survival (OS), but clinical trials have reported conflicting results. METHODS Women presenting with metastatic breast cancer and an intact primary tumor received systemic therapy for 4-8 months; if no disease progression occurred, they were randomly assigned to locoregional therapy for the primary site (surgery and radiotherapy per standards for nonmetastatic disease) or continuing sysmetic therapy. The primary end point was OS; locoregional control and quality of life were secondary end points. The trial design provided 85% power to detect a 19.3% absolute difference in the 3-year OS rate in randomly assigned patients. The stratified log-rank test and Cox proportional hazards model were used to compare OS between arms. Cumulative incidence of locoregional progression was compared using Gray's test. Quality-of-life assessment used standard instruments. RESULTS Of 390 participants enrolled, 256 were randomly assigned: 131 to continued systemic therapy and 125 to early locoregional therapy. The 3-year OS was 67.9% without and 68.4% with early locoregional therapy (hazard ratio = 1.11; 90% CI, 0.82 to 1.52; P = .57). The median OS was 53.1 months (95% CI, 47.9 to not estimable) in the systemic therapy arm and 54.9 months (95% CI, 46.7 to not estimable) in the locoregional therapy arm. Locoregional progression was less frequent in those randomly assigned to locoregional therapy (3-year rate: 16.3% v 39.8%; P < .001). Quality-of-life measures were largely similar between arms. CONCLUSION Early locoregional therapy for the primary site did not improve survival in patients presenting with metastatic breast cancer. Although it was associated with improved locoregional control, this had no overall impact on quality of life.
The Importance of Accurately Defining Gender and Sex in Pathology
Jacobs, Jeremy W. , Lever, J.E. Peabody , Lee, Yeonsoo Sara , Bryan, Katherine M. , Booth, Garrett S. , Njoku, Ihuoma , Araj, Ellen, Lee, Yeonsoo S, Park, Jason Y , Sara Lee, Yeonsoo , Jacobs, Jeremy W , Booth, Garrett , Arvisais‐Anhalt, Simone , Park, Jason Y.

Mayo Clinic

American Journal of Clinical Pathology | January 7, 2022 | Volume: 158 | Issue: 1 | Pages: 153-153

10.1093/ajcp/aqac008 | PMID 35150126 Get It

Incidence, Risk Factors, and Mortality of Clinical and Subclinical Rheumatoid Arthritis–Associated Interstitial Lung Disease: A Population‐Based Cohort
Samhouri, Bilal F. , Vassallo, Robert , Achenbach, Sara J., Kronzer, Vanessa L. , Davis, John M. , Myasoedova, Elena , Crowson, Cynthia S. , Vassallo, Robert , Kronzer, Vanessa L , Myasoedova, Elena , Davis, John M

Mayo Clinic

Arthritis Care & Research | January 7, 2022 | Volume: 74 | Issue: 12 | Pages: 2042-2049

10.1002/acr.24856 | PMID 34995017 Get It

ObjectiveTo identify the incidence, risk factors, and outcomes of rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) and to assess time trends in the incidence and mortality in RA‐ILD.MethodsWe included adult residents of Olmsted County, Minnesota with incident RA between 1999 and 2014. Subjects were followed until death, emigration, or April 30, 2019. ILD was defined as the presence of a radiologist‐defined pattern consistent with ILD on chest computed tomography (CT). When chest CT was absent, the combination of chest radiograph abnormalities compatible with ILD and restrictive pattern on pulmonary function testing was considered consistent with ILD. Potential risk factors included age, sex, smoking, obesity, seropositivity, extraarticular manifestations (EAMs), and medications. For survival analysis, we matched RA‐ILD patients to RA–non‐ILD comparators. The frequency and mortality from clinician‐diagnosed RA‐ILD from 1999 to 2014 was compared against a cohort from 1955 to 1994.ResultsDuring the 1999–2014 time period, 645 individuals (70% women) had incident RA, were a median age of 55.3 years, and 53% never smoked. Twenty‐two patients had ILD before RA, and 51 (67% women) developed ILD during follow‐up. The 20‐year cumulative incidence of RA‐ILD was 15.3%. Ever‐smoking (hazard ratio [HR] 1.92), age at RA onset (HR 1.89 per 10‐year increase), and severe EAMs (HR 2.29) were associated with incident RA‐ILD. The RA‐ILD cases had higher mortality than their matched RA comparators (HR 2.42). Incidence of RA‐ILD was non‐significantly lower from 1999 to 2014 than from 1955 to1994, but mortality was improved.ConclusionsRA‐ILD occurs in nearly 1 in 6 patients with RA within 20 years and is associated with shorter survival. Lack of significant change in RA‐ILD incidence over 6 decades deserves further investigation.
Talus Visualization in Ankle Fractures: How Much Are We Really Seeing?
Hinckley, Nathaniel B. , Karsen, Phillip J. , Deckey, David G. , Fernández, Andrea, Kile, Todd A. , Drakos, Mark C. , Hassebrock, Jeffrey D. , Patel, Karan A.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | January 7, 2022 | Volume: 10 | Issue: 1 | Pages: No page available

10.1177/23259671211066856 | PMID 35024369 Get It

Background: Despite appropriate care, a subset of patients with ankle fractures has persistent pain. This condition may be associated with intra-articular pathology, which is present up to 65% of the time. Purpose: To quantify how much of the talus is visible through an open approach to a standard supination external rotation bimalleolar ankle fracture as a percentage of the entire weightbearing surface of the talus. Study Design: Descriptive laboratory study. Methods: Standard ankle approaches to lateral and medial malleolar fractures were performed in 4 cadaveric ankles from 2 cadavers. Osteotomies were made to simulate a supination external rotation bimalleolar ankle fracture based on the Lauge-Hansen classification. The visible segments of talar cartilage were removed. The tali were then exhumed, and the entire weightbearing superior portion of the talus was assessed and compared with the amount of cartilage removed by an open approach. The mean of the data points as well as the 95% confidence interval were calculated. Results: Four ankle specimens from 2 cadavers were used for these measurements. The mean surface area of the talus was 14.0 cm 2 (95% CI, 13.3-14.7 cm 2 ), while the mean area visible via an open approach was 2.1 cm 2 (95% CI, 0.5-3.6 cm 2 ). The mean proportion of the talus visualized via an open approach was 14.8% (95% CI, 3.6-26.1%). Conclusion: These findings indicate that the true area of weightbearing talar surface visible during an open exposure may be less than what many surgeons postulate. Clinical Relevance: Only a small fracture of the talus is visible via an open approach to the talus during fracture fixation. This could warrant arthroscopic evaluation of these injuries to evaluate and treat osteocondral lesions resulting from ankle fractures.
A new oral testosterone (TLANDO) treatment regimen without dose titration requirement for male hypogonadism
DelConte, Anthony , Papangkorn, Kongnara , Kim, Kilyoung, Bruno, Benjamin, Chidambaram, Nachiappan, Khera, Mohit , Köhler, Tobias , Miner, Martin , Dobs, Adrian S. , Patel, Mahesh, Goldstein, Irwin

Mayo Clinic

Andrology | January 7, 2022 | Volume: 10 | Issue: 4 | Pages: 669-676

10.1111/andr.13153 | PMID 34994093 Get It

AbstractBackgroundMale hypogonadism (testosterone level < 300 ng/dl) is a clinical syndrome that results from failure of the testis to produce physiological levels of testosterone. Most marketed testosterone replacement therapy products often require multiple dose adjustment clinic visits to achieve the desired, eugonadal testosterone levels.ObjectiveTo evaluate the efficacy and safety of a novel oral testosterone undecanoate therapy for the treatment of hypogonadism.Material and methodsNinety‐five (N = 95) hypogonadal men were enrolled in this open‐label, single‐arm, multicenter study in the United States (NCT03242590). Subjects received 225 mg of oral testosterone undecanoate (TLANDO) twice a day for 24 days without dose adjustment. Primary efficacy was percentages of subjects who achieved mean 24‐h testosterone levels within the eugonadal range and secondary efficacies were evaluated based on the upper limit of lab normal range of testosterone concentration.ResultsSubjects enrolled were on average age of 56 years, with about 17% of subjects older than 65 years. The mean body mass index was 32.8 kg/m2. The baseline mean total testosterone values were below the normal range (202 ± 74 ng/dl). Post‐treatment with 450 mg testosterone undecanoate daily dose without dose adjustment, 80% of subjects (95% confidence interval of 72%–88%) achieved a testosterone Cavg in the normal range and restored testosterone levels to mean testosterone Cavg of 476 ± 184 ng/dl at steady state. Testosterone restoration was comparable to other approved testosterone replacement therapy products. TLANDO was well tolerated with no deaths, no drug‐related serious adverse events, and no hepatic adverse events.Discussion and conclusionsTLANDO restored testosterone levels to the normal range in the majority of hypogonadal males. This new oral testosterone replacement therapy can provide an option for no‐titration oral testosterone replacement therapy. This therapy has the potential to improve patient compliance in testosterone replacement therapy.
Bayesian kernel machine regression‐causal mediation analysis
Devick, Katrina L. , Bobb, Jennifer F. , Mazumdar, Maitreyi , Henn, Birgit Claus , Bellinger, David C., Coull, Brent A. , Christiani, David C. , Wright, Robert O. , Williams, Paige L. , Valeri, Linda

Mayo Clinic

Statistics in Medicine | January 7, 2022 | Volume: 41 | Issue: 5 | Pages: 860-876

10.1002/sim.9255 | PMID 34993981 Get It

Greater understanding of the pathways through which an environmental mixture operates is important to design effective interventions. We present new methodology to estimate natural direct and indirect effects and controlled direct effects of a complex mixture exposure on an outcome through a mediator variable. We implement Bayesian Kernel Machine Regression (BKMR) to allow for all possible interactions and nonlinear effects of (1) the co‐exposures on the mediator, (2) the co‐exposures and mediator on the outcome, and (3) selected covariates on the mediator and/or outcome. From the posterior predictive distributions of the mediator and outcome, we simulate counterfactuals to obtain posterior samples, estimates, and credible intervals of the mediation effects. Our simulation study demonstrates that when the exposure‐mediator and exposure‐mediator‐outcome relationships are complex, BKMR‐Causal Mediation Analysis performs better than current mediation methods. We applied our methodology to quantify the contribution of birth length as a mediator between in utero co‐exposure to arsenic, manganese, and lead, and children's neurodevelopmental scores, in a prospective birth cohort in Bangladesh. Among younger children, we found a negative (adverse) association between the metal mixture and neurodevelopment. We also found evidence that birth length mediates the effect of exposure to the metal mixture on neurodevelopment for younger children. If birth length were fixed to its percentile value, the harmful effect of the metal mixture on neurodevelopment is attenuated, suggesting nutritional interventions to help increase fetal growth, and thus birth length, could potentially block the harmful effect of the metal mixture on neurodevelopment.